247 related articles for article (PubMed ID: 22881387)
1. Effects of tuberculosis on the kinetics of CD4(+) T cell count among HIV-infected patients who initiated antiretroviral therapy early after tuberculosis treatment.
Ku NS; Oh JO; Shin SY; Kim SB; Kim HW; Jeong SJ; Han SH; Song YG; Kim JM; Choi JY
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):226-30. PubMed ID: 22881387
[TBL] [Abstract][Full Text] [Related]
2. The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children.
Soeters HM; Sawry S; Moultrie H; Rie AV
J Acquir Immune Defic Syndr; 2014 Oct; 67(2):136-44. PubMed ID: 25072611
[TBL] [Abstract][Full Text] [Related]
3. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.
Karo B; Krause G; Castell S; Kollan C; Hamouda O; Haas W;
BMC Infect Dis; 2017 Jul; 17(1):517. PubMed ID: 28743248
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
[TBL] [Abstract][Full Text] [Related]
5. The effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic review.
Soeters HM; Napravnik S; Patel MR; Eron JJ; Van Rie A
AIDS; 2014 Jan; 28(2):245-55. PubMed ID: 24072197
[TBL] [Abstract][Full Text] [Related]
6. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
Shoko C; Chikobvu D; Bessong PO
S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
[TBL] [Abstract][Full Text] [Related]
7. T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens.
da Silva TP; Giacoia-Gripp CB; Schmaltz CA; Sant Anna FM; Rolla V; Morgado MG
PLoS One; 2013; 8(6):e66095. PubMed ID: 23840403
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral therapy improves survival among TB-HIV co-infected patients who have CD4+ T-cell count above 350cells/mm
Mutembo S; Mutanga JN; Musokotwane K; Alisheke L; Whalen CC
BMC Infect Dis; 2016 Oct; 16(1):572. PubMed ID: 27751168
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.
Nanteza MW; Mayanja-Kizza H; Charlebois E; Srikantiah P; Lin R; Mupere E; Mugyenyi P; Boom WH; Mugerwa RD; Havlir DV; Whalen CC
J Infect Dis; 2011 Sep; 204(6):884-92. PubMed ID: 21849285
[TBL] [Abstract][Full Text] [Related]
10. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.
Cingolani A; Cozzi Lepri A; Castagna A; Goletti D; De Luca A; Scarpellini P; Fanti I; Antinori A; d'Arminio Monforte A; Girardi E
Clin Infect Dis; 2012 Mar; 54(6):853-61. PubMed ID: 22157323
[TBL] [Abstract][Full Text] [Related]
11. Development of opportunistic infections after diagnosis of active tuberculosis in HIV-infected patients.
Kwara A; Carter EJ; Rich JD; Flanigan TP
AIDS Patient Care STDS; 2004 Jun; 18(6):341-7. PubMed ID: 15294084
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study.
Franke MF; Robins JM; Mugabo J; Kaigamba F; Cain LE; Fleming JG; Murray MB
PLoS Med; 2011 May; 8(5):e1001029. PubMed ID: 21559327
[TBL] [Abstract][Full Text] [Related]
13. Rapid suppression of HIV-RNA is associated with improved control of immune activation in Mozambican adults initiating antiretroviral therapy with low CD4 counts.
Almeida JM; Letang E; Nhampossa T; Ayala E; David C; Menendez C; Gascon J; Alonso P; Naniche D
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):705-11. PubMed ID: 21091388
[TBL] [Abstract][Full Text] [Related]
14. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
[TBL] [Abstract][Full Text] [Related]
15. Delay in cART initiation results in persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade of successful HIV suppression.
Ndumbi P; Falutz J; Pant Pai N; Tsoukas CM
PLoS One; 2014; 9(4):e94018. PubMed ID: 24710051
[TBL] [Abstract][Full Text] [Related]
16. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.
Bouteloup V; Sabin C; Mocroft A; Gras L; Pantazis N; Le Moing V; d'Arminio Monforte A; Mary-Krause M; Roca B; Miro JM; Battegay M; Brockmeyer N; Berenguer J; Morlat P; Obel N; De Wit S; Fätkenheuer G; Zangerle R; Ghosn J; Pérez-Hoyos S; Campbell M; Prins M; Chêne G; Meyer L; Dorrucci M; Torti C; Thiébaut R;
HIV Med; 2017 Jan; 18(1):33-44. PubMed ID: 27625009
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
[TBL] [Abstract][Full Text] [Related]
18. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.
Dean GL; Edwards SG; Ives NJ; Matthews G; Fox EF; Navaratne L; Fisher M; Taylor GP; Miller R; Taylor CB; de Ruiter A; Pozniak AL
AIDS; 2002 Jan; 16(1):75-83. PubMed ID: 11741165
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.
Mahan CS; Walusimbi M; Johnson DF; Lancioni C; Charlebois E; Baseke J; Chervenak KA; Mugerwa RD; Havlir DV; Mayanja-Kizza H; Whalen CC; Boom WH;
PLoS One; 2010 Feb; 5(2):e9138. PubMed ID: 20179751
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.
Han SH; Zhou J; Lee MP; Zhao H; Chen YM; Kumarasamy N; Pujari S; Lee C; Omar SF; Ditangco R; Phanuphak N; Kiertiburanakul S; Chaiwarith R; Merati TP; Yunihastuti E; Tanuma J; Saphonn V; Sohn AH; Choi JY;
HIV Med; 2014 Feb; 15(2):77-85. PubMed ID: 23980589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
